OOIR: Observatory of International Research

Papers

(The TQCC of Clinical Genitourinary Cancer is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Significance of Body Surface Area Correction for Cisplatin Eligibility Based on Renal Function of Patients With Muscle-Invasive Bladder Cancer	52
Treatment Patterns and Survival Outcomes Before and After Access to Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma: A Single-Center Retrospective Study From 2004 to 202	47
Does Size Predict Aggressiveness?: Exploring Sporadic Multifocal Tumors in a 10-Year Retrospective Analysis	41
Comparative Efficacy of Avelumab Maintenance Therapy Versus Continued Chemotherapy Followed by Pembrolizumab in Metastatic Urothelial Carcinoma With No Progression After 4 Cycles of Chemotherapy: A Re	34
Does Chemo-Radiotherapy Improve Survival Outcomes vs. Radiotherapy Alone for High-Grade cT1 Urothelial Carcinoma of the Bladder?	32
Treatment patterns and outcomes for younger patients with metastatic castration-resistant prostate cancer (mCRPC); An Australian prospective registry study	30
Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors	28
Metastasis Within Three Years from Radical Nephroureterectomy as a Potential Surrogate for Overall Survival	26
The Impact of a Multidisciplinary Tumor Board (MTB) on Treatment Decision Making for Patients With Renal Cell Carcinoma (RCC): 5-Year Data Analysis	26
Editorial Board	26
Establishing a Prognostic Model Based on Three Genomic Instability-related LncRNAs for Clear Cell Renal Cell Cancer	26
The Impact of Concomitant Medications on the Overall Survival of Patients Treated with Systemic Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysis	25
Neoadjuvant Chemoradiotherapy Followed by Radical Cystectomy for Muscle-Invasive Bladder Cancer: Analysis of Efficacy and Safety in 119 Patients	24
Treatment Intensification With Novel Hormonal Therapy in Castration-Sensitive Prostate Cancer: Patient Identification and Clinical Rationale	24
Efficacy and Safety of Intravesical Gemcitabine and Docetaxel Combination Therapy in Patients With Intermediate- and High-Risk Non–Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis	24
Treatment Patterns and Clinical Outcomes Among Patients With Metastatic Prostate Cancer Harboring Homologous Recombination Repair Mutations	23
Adjuvant Immunotherapy in High-Risk Muscle-Invasive Urothelial Cancer: An Updated Meta-Analysis of Randomized Controlled Trials	22
The Role of Prior Bladder Cancer on Recurrence in Patients Treated with Radical Nephroureterectomy	21
Comparison of Cabozantinib and Axitinib as Second-line Therapy After Nivolumab Plus Ipilimumab in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Comparative Analysis of Retrospective Real	20
Metastasis Profile and Survival Outcomes of Metastatic Non-Muscle Invasive Bladder Cancer: A National Cancer Database Analysis	20
The Distribution of Metastatic Renal Cell Carcinoma by Presenting Tumor Stage in the Modern Era	20
Pseudoprogression and Mixed Responses in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab: A Retrospective Analysis	20
Real-World Effectiveness and Treatment Persistence of Darolutamide, Apalutamide, and Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer: A Multicenter Study	19
Early Safety and Efficacy Profile of Homogeneously Dosed Salvage Stereotactic Body Radiotherapy (SBRT) for Intraprostatic Recurrences After Low Dose Rate (LDR) Brachytherapy	19
Real-World Analysis of Treatment Patterns and Platinum-Based Treatment Eligibility of Patients With Metastatic Urothelial Cancer in 5 European Countries	19

Urine Cytology Rarely Escalates Clinical Management in the Surveillance of Non–muscle-Invasive Bladder Cancer	19
Real-World Treatment Patterns and Outcomes in Patients With Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: A Multicountry Medical Chart Review	19
Cabozantinib in the First-Line Treatment of Patients With Metastatic Renal Cell Carcinoma, Real-World Data From the Czech Republic and Poland: ICARO-RC Project	19
Advanced Age Impacts Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma	19
Real-World Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma	19
Incidence and Survival of Patients With Prostate Cancer in North-Rhine Westphalia, Germany	18
Impact of Preoperative Plasma Potassium Levels on Oncological Outcomes, Major Complications, and 30-Day Mortality in Bladder Cancer Patients Undergoing Radical Cystectomy	18
Survival Outcomes by Race Following Surgical Treatment for Upper Tract Urothelial Carcinoma	18
Detection of Apical Cancer with Novel Imaging Modalities to Predict Apical Margin Positivity in Robotic Assisted Radical Prostatectomy	18
Relationship Between Pretreatment Body Composition and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Ipilimumab Plus Nivolumab	17
The Impact of Radical Prostatectomy Versus Radiation Therapy on Cancer-Specific Mortality for Nonmetastatic Prostate Cancer: Analysis of an Other-Cause Mortality Matched Cohort	17
Real-World Outcomes of Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Retrospective Analysis	17
Appearance of New Lesions Associate With Poor Prognosis in Pembrolizumab-Treated Urothelial Carcinoma	17
Cardiovascular Disease in a Population-based Cohort of Prostate Cancer Patients with Long Term Follow Up	17
Editorial Board	16
Dose-Dense Docetaxel and Radium-223 in Bone-Dominant Metastatic Castration-Resistant Prostate Cancer	16
Table of contents	16
The Importance of Repeat Imaging Prior to Treatment Decision-making in Testicular Cancer: Commentary From the Inaugural Global Society of Rare Genitourinary Tumors Summit	16
Outcomes of Intraoperative Frozen Section Examination of Surgical Resection Margins of the Penis in Penile Cancer	15
Preoperative Immunonutrition Significantly Reduced Surgical Site Infection After Urinary Diversion for Invasive Bladder Cancer: A Retrospective Cohort Study	15
Outcomes for Patients With SPOP Mutated Castration-Resistant Prostate Cancer (CRPC) Treated With an Androgen Receptor Pathway Inhibitor (ARPI)	15
A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer	15
Perioperative and Survival Outcomes of Patients Treated With Robot-Assisted Partial Nephrectomy and Percutaneous Microwave Ablation for Small Renal Masses: A Single Center Experience	15
Prostate Cancer Incidence by Age and Clinicopathological Characteristics: A Population-Based Study in Girona, Spain, 2010 to 2021	15
Analysis of Clinicopathologic Features and Imaging Findings of TFE3-Rearranged Renal Cell Carcinoma	14
Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma	14
Clinical Outcomes and Prognostic Factors in Patients With Penile Carcinoma: A Sub-Analysis From Meet-URO 23 (I-RARE) Registry Study	14
mRNA-Based Urine Test Performance in High and Very-High Risk Non–Muscle-Invasive Bladder Cancer Patients Undergoing Contextual Endoscopic Follow-up (VERNAL: Vesical Tumor Early Monitoring: mRNA-Based	14
Single-Dose Post-Office Fulguration Mitomycin C Instillation Appears to Improve Recurrence-Free Survival in Patients With Low-Grade Noninvasive Bladder Cancer	14
Comparisons of Pembrolizumab Plus Lenvatinib, Nivolumab Plus Cabozantinib, and Cabozantinib Monotherapy in Advanced Non-Clear Cell Renal Cell Carcinoma Based on Individual Patient Data Reconstruction	14
Development and Validation of Prognostic Model for Metastatic Castration-Resistant Prostate Cancer Patients Treated With First-Line Abiraterone or Enzalutamide	13
Table of contents	13
Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry	13
Adverse Events of Cabozantinib Plus Nivolumab Versus Ipilimumab Plus Nivolumab	13
Expression and Prognostic Significance of Different Antibody-Drug Conjugate Target Proteins in Urachal Carcinoma	13
Impact of Novel Hormonal Agents (Abiraterone, Enzalutamide) on the Development of Visceral and/or Brain Metastases in Patients With Bone-metastatic Castration-resistant Prostate Cancer	13
Two Clinical Cases of Li-Fraumeni Syndrome and Prostate Cancer: Genetic Counseling and Clinical-Surgical Management	12
Macrophage Cell and Diagnostic Biomarkers in BLCA: Integrating Machine Learning With Single-Cell Analysis	12
Adherence Outcomes and Risk Factors Predicting Nonadherence to Active Surveillance in Patients With Stage 1 Testicular Germ Cell Tumors	12
Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozant	12
The Use of Lurbinectedin for the Treatment of Small Cell and Neuroendocrine Carcinoma of the Prostate	12
Urinary Exosomal miR-17-5p Accelerates Bladder Cancer Invasion by Repressing its Target Gene ARID4B and Regulating the Immune Microenvironment	12
Oral Toxicities of PSMA-Targeted Therapies: Mitigation Strategies and Translational Opportunities	12
Predicting Treatment Effects from Surrogate Endpoints in Historical Trials in First-Line Metastatic Castration-Resistant Prostate Cancer	12
Chronic Glucocorticoid Use and Risk for Advanced Prostate Cancer at Presentation: A SEER-Medicare Cohort Study	12
Regional Differences in Stage III Nonseminoma Germ Cell Tumor Patients Across SEER Registries	11
Central Nervous System Disease Progression Among Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Case Series	11
NODESAFE Nomogram: A Novel Score System to Predict Lymph Node Involvement at the Time of Nephrectomy or Nodal Recurrence in Nonmetastatic Renal Cell Carcinoma	11
Sarcopenia in Men With Bone-Predominant Metastatic Castration-Resistant Prostate Cancer Undergoing Ra-223 Therapy	11
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)	11

Survival After Cryotherapy Versus Radiotherapy in Low and Intermediate Risk Localized Prostate Cancer	11
Role of Renin-Angiotensin System Blockers on BCG Response in Nonmuscle Invasive, High Risk Bladder Cancer	11
Non-Immunotherapy Arm Allocations in Phase 3 Genitourinary Cancer Trials with Immunotherapy	11
Prostate-specific antigen level association with COVID-19 infection and vaccination	11
An Update on Focal Therapy for Prostate Cancer	11
Activity of Platinum Chemotherapy in Men With Prostate Cancer With and Without DNA Damage Repair Mutations	11
Role of Race and Insurance Status in Prostate Cancer Diagnosis-to-Treatment Interval	11
Analysis of Imaging and Pathologic Features in Eosinophilic Solid and Cystic Renal Cell Carcinoma	11
Proposal for a New Vesical Imaging-Reporting and Data System (VI-RADS)-Based Algorithm for the Management of Bladder Cancer: A Paradigm Shift From the Current Transurethral Resection of Bladder Tumor	11
Identification of Different miRNAs and Their Relevant miRNA Targeted Genes Involved in Sister Chromatid Cohesion and Segregation (SCCS)/chromatin Remodeling Pathway on T1G3 Urothelial Carcinoma (UC) R	11
Discovery of TBK1-Associated Oncogenic Mechanisms in Patients With Upper Tract Urothelial Carcinoma and Pre-Existing End-Stage Renal Disease	11
Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor	11
Analysis of Neoadjuvant Immunotherapy and Chemotherapy for Muscle-Invasive Bladder Cancer in a National Registry	11
LuRa: Efficacy and Safety of Radium-223 Following [177Lu]Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer	11
Neoadjuvant Versus Adjuvant Chemotherapy in Non-Metastatic Locally-Advanced Stage Radical Cystectomy Candidates	10
Integration of Multiparameter MRI into Conventional Pretreatment Risk Factors to Predict Positive Surgical Margins After Radical Prostatectomy	10
The Prognostic Significance of Homologous Recombination Repair Pathway Alterations in Metastatic Hormone Sensitive Prostate Cancer	10
Association Between Perioperative Chemotherapy and Survival in Men Undergoing Radical Resection for Primary Urethral Urothelial Carcinoma: An Analysis of the National Cancer Database	10
Small Cell Bladder Cancer: Treatment Patterns for Local Disease and Associated Outcomes. A Retrospective Cohort Study	10
Integral Approach in the Follow-up of Prostate Cancer Patients: SOGUG Multidisciplinary Expert Panel Insights	10
Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors	10
Site-Specific Differences of Eligibility for Adjuvant Immunotherapy Among Urothelial Carcinoma Patients Treated With Radical Surgery: Results From a Multicenter Cohort Study	10
Differences in Survival of Clear Cell Metastatic Renal Cell Carcinoma According to Partial vs. Radical Cytoreductive Nephrectomy	10
Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal Cancer	10
Efficacy and Safety of Combination AKT and Androgen Receptor Signaling Inhibition in Metastatic Castration-Resistant Prostate Cancer: Systematic Review and Meta-Analysis	10
Value of Cystatin C-Based Sarcopenia Index in Patients Undergoing Surgery for Renal Tumors	10
Survival and Economic Impact of Rapid Prostate-Specific Antigen Doubling Time in Patients With Nonmetastatic Castration-Resistant Prostate Cancer	10
Investigating the Potential to Offer Reproductive Organ Preserving Radical Cystectomy to More Female Bladder Cancer Patients	10
Testicular Radiomics To Predict Pathology At Time of Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Tumor	10
Factors Associated With Palliative Intervention Utilization for Metastatic Renal Cell Carcinoma	10
The Role of Cytoreductive Nephrectomy in Contemporary Metastatic Renal Cell Carcinoma: An Other-Cause Mortality Match Population-Based Study	10
Disulfidptosis-Related LncRNA Signatures for Prognostic Prediction in Kidney Renal Clear Cell Carcinoma	10
Does the Gleason Score 7 Upgrading Always Predict Worse Prognosis?	10
The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A systematic review and meta-analysis	10
Incidence of Germline Variants in Familial Bladder Cancer and Among Patients With Cancer Predisposition Syndromes	9
Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin	9
Clinical Outcomes and Risk Stratification in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With New-Generation Androgen Receptor Signaling Inhibitors	9
Lymphovascular Invasion is Predictive for Adjuvant Platinum Therapy Benefit in Urothelial Bladder Cancer	9
Patterns of Utilization and Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced-urothelial Bladder Cancer (LABC)-Real World Data From an Indian Tertiary Care Cancer Center	9
Effectiveness of the Continuous Care Model on Quality of Life, Sexual Satisfaction and Function in Bladder Cancer Patients Undergoing Tumor Resection Surgery: A Randomized Control Trial	9
Erdafitinib versus Chemotherapy in Fibroblast Growth Factor Receptor-Altered Advanced or Metastatic Urothelial Cancer After Progression on Anti-programmed Death-(Ligand) 1 Therapy: An Exploratory Anal	9
A Panel-Based Mutational Signature of Mismatch Repair Deficiency is Associated With Durable Response to Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer	9
A Systematic Review and Meta-Analysis of the Role of Immune Checkpoint Inhibitors (ICI) as Adjuvant Treatment for Localized High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC)	9
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma	9
RNA sequencing in a penile cancer cohort: an investigation of biomarkers of cisplatin resistance and potential therapeutic drug targets	9
Analysis of Neoadjuvant Chemotherapy Utilization, Pathologic Response, and Overall Survival in Upper Tract Urothelial Carcinoma	9
Total Prostate Specific Antigen in Prostate Cancer Screening in Hyperglycemic Individuals	9
Bladder tumor Resection Weight as a Prognostic Factor for Recurrence and Progression in Patients With High-Risk Non-Muscle Invasive Bladder Treated With BCG	9
Urological Cancers and ChatGPT: Comment	9
Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25)	9
A Systematic Review of Clinical Trials Comparing Radiation Therapy Versus Radical Prostatectomy in Prostate Cancer	9
Treatment Patterns and Outcomes in Lymph-Node-Positive (pN1) Prostate Cancer: A National Cancer Database Study	9
The Risk of Catastrophic Healthcare Expenditures Among Prostate and Bladder Cancer Survivors in the United States	9
Urological Cancers and ChatGPT: Assessing the Quality of Information and Possible Risks for Patients	9
Regional Lymph Node Dissection is associated with Improved Survival for Patients with Urothelial Cell Carcinoma Undergoing Definitive Surgery	9
Clinical Significance of Intraductal Carcinoma of the Prostate After High-Dose Brachytherapy With External Beam Radiation Therapy: A Single Institution Series and an Updated Meta-Analysis	9
Temporal Trends and Cancer-Specific Mortality in Nonmetastatic Muscle-Invasive Urothelial Carcinoma of the Urinary Bladder Treated With Trimodal Therapy	9
Clinical Management of Synchronous and Metachronous Renal Lesions in Patients With Oncocytoma Treated With Nephrectomy: A 30-Year Single-Center Experience	9
Paratesticular Sarcoma: Analysis of Oncological Outcomes and Prognostic Factors	8
Comprehensive Evaluation of Androgen Receptor Pathway Inhibitors in Metastatic Castration-Sensitive Prostate Cancer: A Multicenter Inverse Probability of Treatment Weighting-Based Study	8
Patient-Reported Outcomes and Long-Term Toxicity in stage I TGCT: A Retrospective Single-Center Cohort (1994-2023)	8
Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study	8
Cancer-Specific Mortality Differences in Specimen-Confined Radical Prostatectomy Patients According to Lymph Node Invasion	8
A Systematic Review and Meta-Analysis of the Significance of Diabetes on Kidney Cancer Outcomes and the Role of Metformin	8
Trends and Disparities in Prostate Cancer Mortality in the United States (1999–2020)	8
A Real-World Prospective Study of Comprehensive Genomic Testing in Patients with Metastatic Castration-Resistant Prostate Cancer	8
Impact of Muscle Depletion on Prognosis in Patients Undergoing Radical Cystectomy	8
Survival Disparities by Sex, Race, and Age in the Era of Contemporary Advanced Urothelial Carcinoma Therapy: A Real-World Analysis	8
Editorial Board	8
Association Between Early on-Treatment Weight Loss With Enfortumab Vedotin Plus Pembrolizumab and Survival in Advanced Urothelial Carcinoma	8
Real-World Treatment Patterns and Effectiveness of Patients With Advanced Renal Cell Carcinoma: A Nationwide Observational Study	8
Differential tumor response patterns and extent of necrosis after immunotherapy combinations predict clinical responses for renal cell carcinoma	8
The Prognostic Role of 68GA-PSMA-PET/CT in Metastatic Hormone-Sensitive Prostate Cancer: A Preliminary Analysis	8
The Clinicopathological Characteristics and Prognosis of 55 Patients With TFE3-Rearranged Renal Cell Carcinomas	8
Local treatment Associated With Prognosis among Men With Metastatic Prostate Cancer: A SEER-Based Study	8
Epidemiology, Management, and Survival Outcomes of Germ Cell Cancer in Southern Portugal: A Population-Based Study (2008-2012)	8
Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice	8
Deterioration in Physical Fitness and Changes in Body Composition After Cisplatin-Based Chemotherapy for Metastatic Testicular Cancer	8
The Role of Radical Cystectomy in Clinically Node Positive Bladder Cancer: A US Veterans Health Administration Study	7
Prognostic Impact of Bone Metastasis in Patients With Metastatic Urothelial Carcinoma Treated With Durvalumab With or Without Tremelimumab in the DANUBE Study	7

Efficacy of Inpatient, Evidence-Based Tobacco Use Treatment of Patients With Bladder Cancer After Radical Cystectomy	7
Pathogenic Germline Variant Prevalence and Genetic Testing Outcomes in Patients With Urothelial Carcinoma	7
Efficacy and Safety of Immune Checkpoint Blockade in Locally Advanced or Metastatic Penile Cancer: A Systematic Review and Meta-Analysis	7
Demographic Profiles and Survival Outcomes of Patients With Urachal Adenocarcinoma: A Rare Tumor of the Urachal Remnant	7
Geographic Distribution of Racial Differences in Renal Cell Carcinoma Mortality	7
Opioid Use in Patients With Testicular Cancer: Patterns and Risk Factors	7
Clinically Meaningful Upstaging and Upgrading in Favorable Intermediate-Risk Radical Prostatectomy Patients	7
Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter Study	7
Radical Prostatectomy Versus Radiation Therapy for Locally Advanced and Clinically Nodal Positive Prostate Cancer	7
A Multi-Center Comparative Analysis of the G8-Score and Charlson Comorbidity Index as General Health Assessment Tools in Older Patients With Prostate Cancer	7
Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients	7
Advances in Androgen Deprivation Therapy–Sparing Strategies: Ongoing Studies in Metastatic Castration-Sensitive Prostate Cancer	7
Outcomes of Consolidative Nephrectomy following Primary Immunotherapy in Advanced Renal Cell Carcinoma: A Multicenter Analysis	7
Healthcare Resource Use and Costs of Localized Prostate Cancer Patients in Finland	7
Metastatic Pure Seminomas With Early Relapse: Prognostic Roles of High Dose Chemotherapy and Surgery of Residual Disease	7
Patient Perceptions Regarding Routine Oncologic Follow-Up for Urologic Malignancies	7
A Comparison of ChatGPT and Human Questionnaire Evaluations of the Urological Cancer Videos Most Watched on YouTube	7
Pretreatment Lymphocyte to C-Reactive Protein Ratio: An Independent Predictor of Overall Survival in Metastatic Hormone-Naïve Prostate Cancer Patients	7
Corrigendum	7
Utilization Patterns and Survival in Older Men With Metastatic Prostate Cancer Treated with Radium-223 in the United States: A SEER-Medicare Study	6
A SEER-Medicare Based Quality Score for Patients With Metastatic Upper Tract Urothelial Carcinoma	6
Dose Intensity in Real-World Patients With Metastatic Renal Cell Carcinoma Taking Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors	6
Editorial Board	6
Phase 2 Study of Neoadjuvant FGFR Inhibition and Androgen Deprivation Therapy Prior to Prostatectomy	6
Treatment Patterns Among Androgen Receptor Pathway Inhibitor-Experienced Patients With Metastatic Castration-Resistant Prostate Cancer: A Global Real-World Study	6
The Impact of Covid-19 Pandemic on Genitourinary Cancers Stage and Grade	6
Secondary Malignancy After EBRT: A Closer Look at Absolute Risk and Follow-Up	6
Distinct Profiles of DNA Repair Activity Define Favorable-risk Prostate Cancer Subtypes With Divergent Outcome	6
Diagnostic and Prognostic Value of Neutrophil-Lymphocyte Ratio in Adrenocortical Carcinoma	6
Table of contents	6
Albumin-to-Alkaline Phosphatase Ratio as a Novel Prognostic Factor in Patients Undergoing Nephrectomy for Non-Metastatic Renal Cell Carcinoma: Propensity Score Matching Analysis	6
Evaluation of the Prognostic Role of TP53 Gene Mutations in Prostate Cancer Outcome: A Systematic Review and Meta-Analysis	6
Study Endpoint Fulfillment and FDA Approval Success in Phase III Clinical Trials of Genitourinary Malignancies	6
Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse Even	6
Effect of NSAID Consumption on Renal Cell Carcinoma Prognosis: A Population-Based Study	6
Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison	6
Effect of Positive Surgical Margins in Patients Who Undergo a Partial Nephrectomy Regarding Recurrence, Overall Survival, Recurrence/Progression-Free Survival, and Metastasis-Free Survival. A Systemat	6
Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)	6
Baseline and Dynamic Changes in Hemoglobin Levels Predict Treatment Response and Prognosis in Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study	6
Outcomes of Radical Radiotherapy for the Treatment of Localized Renal Pelvic and Ureteral Carcinoma Intolerant to Surgery: A Real-World Study	6
Table of contents	6
Multicenter Database of Patients with Germ-Cell Tumors: A Latin American Cooperative Oncology Group Registry (LACOG 0515)	6
Clinical Presentation and Targeted Interventions in Urachal Adenocarcinoma: A Single-Institution Case Series and Review of Emerging Therapies	6
Combining CAPRA-S With Tumor IDC/C Features Improves the Prognostication of Biochemical Recurrence in Prostate Cancer Patients	6
Long-term Clinical Outcomes of Patients With Negative Pathology (pN0) at Primary Retroperitoneal Lymph Node Dissection	6
The Prognostic Value of Human Papillomavirus Status in Penile Cancer: Outcomes From a Norwegian Cohort Study	6
RC48-Antibody-Drug Conjugate in Metastatic Urothelial Carcinoma: A Multicenter Real-World Study in China	6
Markers in Identifying Pathological Complete Response Status in Muscle Invasive Bladder Cancer Patients Who Achieved Clinical Complete Response After Neoadjuvant Chemotherapy	6
Influence of Tumor Characteristics and Time to Metastatic Disease on Oncological Outcomes in Metachronous Metastatic Prostate Cancer Patients	6
Combination Chemotherapy With TS-1 and Cisplatin for Urinary Adenocarcinoma: A Retrospective Case Series	6
Comment on “Evaluating Biomarkers for Testosterone Replacement Efficacy in Testicular Cancer Survivors With Mild Leydig Cell Insufficiency”	6
Clinical, Prognosis, and Treatment Effect Features Analysis of Metachronous and Synchronous UTUC and BUC	6
Creatinine-Cystatin C Ratio as a Promising Prognostic Biomarker in Patients With UTUC After Radical Nephroureterectomy	6
Association of Androgen Deprivation Therapy with Metabolic Disease in Prostate Cancer Patients: An Updated Meta-Analysis	6
Table of contents	6
Clinical Factors Associated With Pathological Grade Group 1 Patients in D'Amico Intermediate-Risk Group Following Robot-Assisted Radical Prostatectomy: A Retrospective Multicenter Cohort Study in Japa	6
Comprehensive Analyses Revealed Eight Immune Related Signatures Correlated With Aberrant Methylations as Prognosis and Diagnosis Biomarkers for Kidney Renal Papillary Cell Carcinoma	6
Association of Prehabilitation in the Precystectomy Pathway in Patients With Bladder Cancer on Postoperative Outcomes	6
Treatment Discontinuation in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Lutetium-177 (177Lu)–PSMA-617: A Retrospective Real-World Study	6
Pathological Response and Outcomes in Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Immunotherapy-Based Therapies and Undergoing Deferred Cytoreductive Nephrectomy (CN)	6
Prognostic Implications of Patients With Clinically Node Positive Bladder Cancer Undergoing Radical Cystectomy	5
Complications in the Early Recovery Period After Radical Cystectomy—Real Data From Impartial Inpatient Rehabilitation	5
A randomized double-blind single center study of testosterone replacement therapy or placebo in testicular cancer survivors with mild Leydig cell insufficiency (Einstein-intervention)	5
A Clinical Nomogram for Predicting Overall Survival in Patients With T1/T2 Penile Squamous Cell Carcinoma	5
Late Relapse of Germ Cell Tumors After Prior Chemotherapy or Surgery-only	5
Hydronephrosis as a Prognostic Factor in Primary Bladder Adenocarcinoma: Insights from a 15-Year Tertiary Center Experience	5
Impact of Variant Histology on Oncological Outcomes in Upper Tract Urothelial Carcinoma: Results From the ROBUUST Collaborative Group	5
Impact of Impaired Renal Function on the Efficacy and Safety of Enfortumab Vedotin Monotherapy in a Multicenter Real-World Cohort of Patients With Metastatic Urothelial Cancer: YUSHIMA Study	5
Association of PD-L1 and PD-1 Expression With Clinicopathological Characteristics and Prognosis in Upper Tract Urothelial Carcinoma	5
Germline DNA Repair Genes Pathogenic Variants Among Mexican Patients With Prostate Cancer	5
CD70 is Consistently Expressed in Primary and Metastatic Clear Cell Renal Cell Carcinoma	5
10-yr Results of Moderately Hypofractionated Postoperative Radiotherapy for Prostate Cancer Focused on Treatment Related Toxicity	5
Real-world Treatment Sequencing and Outcomes With Cabozantinib After First-line Immune Checkpoint Inhibitor-based Combination Therapy For Patients With Advanced Renal Cell Carcinoma: CARINA Study Resu	5
Tumoral Ki67 and PSMA Expression in Fresh Pre-PSMA-RLT Biopsies and Its Relation With PSMA-PET Imaging and Outcomes of PSMA-RLT in Patients With mCRPC	5
The Incidence of Extreme Serum Prostate Specific Antigen Levels During the COVID-19 Pandemic	5
Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer	5
Long-Term Mortality Trends From Prostate Cancer and Associated Second Malignancies in the U.S., 1999 to 2023: Implications for Survivorship Care	5
Impact of 18 FDG- PET CT in the Management of Muscle Invasive Bladder Cancer	5
Focal High-Intensity Focused Ultrasound vs. Active Surveillance for ISUP Grade 1 Prostate Cancer: Medium-Term Results of a Matched-Pair Comparison	5
CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC	5
Predictors of Response Following Neoadjuvant Cisplatin-Based Chemotherapy for Muscle Invasive Urothelial Bladder Cancer Using Molecular Profile: A Prospective Clinical Study	5
Does Physician Documentation of Patients’ Prostate-Specific Antigen Doubling Time Affect Treatment Decisions in High-Risk Biochemically Recurrent Prostate Cancer?	5
ATR Inhibition in Advanced Urothelial Carcinoma	5
Impact of Renin-Angiotensin System Inhibitors on Response to PD1/L1 Inhibitors in Patients With Metastatic Renal Cell Carcinoma	5
PARP Inhibitors in Metastatic Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis of Existing Evidence	5
Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Urothelial Cancer	5
Prostate Cancer Screening: Empirical Clinical Practice, Not Evidence-Based	5
Optimizing the Use of Next-Generation Sequencing Assays in Patients With Urothelial Carcinoma: Recommendations by the 2023 San Raffaele Retreat Panel	5
Chemotherapy-Induced Peripheral Neuropathy (CIPN) as a Predictor of Decreased Quality of Life in Testicular Germ Cell Tumor Survivors	5
Impact of Multiparametric MRI and PSA Density on the Initial Indication or the Maintaining in Active Surveillance During Follow-Up in low-Risk Prostate Cancer	5
Prognostic Significance of Radiographic Lymph Node Invasion in Contemporary Metastatic Renal Cell Carcinoma Patients	5
Predictors of Survival and Recurrence After Partial or Radical Nephrectomy in Women with Localized Renal Cell Carcinoma: A Multicenter Analysis	5
Sex Does Not Affect Survival: A Propensity Score-Matched Comparison in a Homogenous Contemporary Radical Cystectomy Cohort	5
Trends in Treatment Patterns and Outcomes Among Patients Diagnosed With Nonmuscle-Invasive Bladder Cancer in the United States	5
Letter to the Editor: Transperineal Versus Transrectal Prostate Biopsy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials	5